Asian flu vaccine provider Adimmune is continuing with patient enrolment for its Phase III trial of Quadrivalent Influenza Vaccine in Europe.
The quadrivalent flu vaccines are designed to protect against four different flu viruses: two influenza A and two influenza B.
With the number of patients recruited crossing 1,000, the Phase III trial is the largest clinical trial held in
Europe, initiated by a Taiwanese vaccine company and is considered as a milestone for Adimmune to begin selling its own-brand product in Europe.
Enrolment for the study is expected to close by the end of this year.
Meanwhile, strategic collaboration between Adimmune and Techdow Pharmaceutical has obtained approval to manufacture Enoxaparin Sodium pre-filled syringes in Poland and other sites within the European Union (EU).
The collaboration was initiated in 2013, under which Techdow provided Enoxaparin API, while Adimmune provides a pre-filled syringe filling service and ships to Europe.
Europe has strong demand for enoxaparin sodium and Adimmune expects the usage rate of its PFS production line to quickly increase after mass production.
